small molecule

TEGSEDI

INOTERSEN SODIUM

Loss of exclusivityApril 2031latest FDA-listed patent expiry

CompanyAkcea Therapeutics →View the full company profile on CliffBio

Drug detail

Brand name	TEGSEDI
Active ingredient	INOTERSEN SODIUM
Strength	EQ 284MG BASE/1.5ML (EQ 189.3MG BASE/ML)
Dosage form	SOLUTION
Route	SUBCUTANEOUS
Modality	Small molecule
FDA approval	October 2018
Marketing status	DISCN

Listed patents

Patent	Expires	Type
9399774	April 2031	use U-2430
9061044	April 2031	substance
8697860	April 2031	product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.